STOCK TITAN

Surmodics Inc - SRDX STOCK NEWS

Welcome to our dedicated page for Surmodics news (Ticker: SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.

About Surmodics Inc.

Surmodics Inc. (SRDX) is a company deeply embedded in the medical device, diagnostic, and life sciences sectors. Known for its significant contributions in coating technologies and now its evolving whole-product solutions, the company partners with leading and emerging players to transform how medical devices address complex challenges. With a robust background in developing advanced coatings, Surmodics has built a reputation for innovating in areas crucial to improving the detection and treatment of diseases.

Business Model & Core Solutions

Historically, Surmodics has specialized in the development of coating technologies that enhance the performance and safety of a wide range of medical devices. The company has now broadened its scope to provide comprehensive product solutions. This transformation is driven by a strategy of integrating innovative coatings with additional functionalities that help in the detection and treatment of diseases. At its core, the company leverages deep scientific expertise and cutting-edge engineering to deliver solutions that address critical challenges in the healthcare industry.

Partnerships and Industry Expertise

Surmodics collaborates with some of the world's most respected medical device, diagnostic, and life sciences companies. These partnerships enable the company to remain at the forefront of technological advancements across multiple sectors. By combining industry-specific insights with a history of research and development excellence, Surmodics consistently addresses industry needs with customized solutions. The company’s commitment to quality and innovation underscores its standing as a trusted partner in the healthcare ecosystem.

Competitive Landscape and Market Position

Operating within a competitive and innovation-driven industry, Surmodics distinguishes itself through its ability to move beyond traditional coating technologies. Its strategic acquisitions and broadened product offerings have repositioned the company to offer whole-product solutions that cater to complex medical challenges. Surmodics’ systematic approach to problem solving, which integrates both advanced coatings and product development, provides a unique competitive edge. This repositioning allows the company to respond effectively to the evolving needs of healthcare providers.

Technological Innovations and Operational Excellence

The evolution at Surmodics is marked by continual investment in research and development, targeted at solving critical issues in medical devices and diagnostics. The company employs advanced technologies and engineering practices to enhance product performance and reliability. By addressing the intricate demands of medical technology through innovation and strategic problem solving, Surmodics serves as a prime example of how scientific research can be translated into practical, life-improving solutions. Its operational model emphasizes steady improvements, robust quality control, and a continuous drive to adapt to emerging technological trends.

Integrated Solutions for a Changing Industry

Surmodics’ transformation from being a provider of coating technologies to a developer of whole-product offerings is a response to the increasing complexity of medical device challenges. The company integrates several facets of product design, from innovative materials science to detailed engineering processes, ultimately delivering products that meet detailed clinical requirements. This holistic view enables Surmodics to streamline the process of medical device development, thereby ensuring that the products not only perform reliably but also contribute significantly to improving patient outcomes through enhanced disease detection and treatment capabilities.

Commitment to Technological Excellence and Healthcare Impact

At its foundation, Surmodics is dedicated to improving healthcare delivery by addressing difficult challenges inherent in medical device performance. The continuous drive for technological excellence and the willingness to evolve have kept the company relevant in an era where healthcare innovation is paramount. Surmodics’ ability to combine technical expertise with strategic partnerships places it in an advantageous position to assist clients in overcoming hurdles associated with medical device development. Investors and industry professionals can view this approach as a reaffirmation of the company’s commitment to operational excellence and impactful technology solutions.

Rhea-AI Summary
Surmodics, Inc. will present 24-month data from the SWING Trial, evaluating the Sundance™ Sirolimus Drug-Coated Balloon's safety and performance in treating occlusive lesions in the infra-popliteal arteries. The trial reports an 8.3% major adverse event rate at 6 months and an 80% target lesion primary patency rate at 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced that 36-month data from its TRANSCEND clinical trial will be presented at the 50th Annual VEITH Symposium. Dr. Peter A. Schneider will share the trial's safety and efficacy data in a session focused on randomized controlled trial updates on drug coated balloons and drug eluting stents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary
Surmodics, Inc. has launched Preside hydrophilic coatings, its most advanced medical device coating technology. The coatings offer low-friction and low-particulate generation, improving distal access for neurovascular applications and crossing for challenging coronary lesions. The coatings are formulated to balance enhanced lubricity and coating durability. Surmodics has secured the first 510(k) device clearance for this technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
Rhea-AI Summary
Surmodics, Inc. to release Q4 2023 financial results on November 8
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
conferences
-
Rhea-AI Summary
Surmodics, Inc. (SRDX) reported a total revenue of $52.5 million, a 111% increase year-over-year, with a GAAP Diluted EPS of $0.52. The company obtained FDA premarket approval for the SurVeil DCB, leading to a $27 million milestone payment, and received FDA 510(k) clearance for its Pounce LP Thrombectomy System. Medical Device revenue grew by 163%, while In Vitro Diagnostics revenue decreased by 12%. Surmodics now expects fiscal year 2023 total revenue to range from $130 million to $132 million, representing an increase of 30% to 32% compared to the prior year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.11%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags

FAQ

What is the current stock price of Surmodics (SRDX)?

The current stock price of Surmodics (SRDX) is $30.89 as of April 1, 2025.

What is the market cap of Surmodics (SRDX)?

The market cap of Surmodics (SRDX) is approximately 549.5M.

What is the core business of Surmodics Inc.?

Surmodics Inc. focuses on developing advanced coating technologies and integrated product solutions for the medical device, diagnostic, and life sciences industries.

How does Surmodics generate revenue?

Revenue is primarily generated through strategic collaborations and partnerships with medical device, diagnostic, and life sciences companies, leveraging their expertise in technology development and product innovation.

What sets Surmodics apart from its competitors?

Surmodics distinguishes itself by evolving from a provider of solely coating technologies to offering comprehensive, whole-product solutions that address complex healthcare challenges.

What industry challenges does Surmodics address?

The company targets critical issues including the reliability and performance of medical devices, enabling improved detection and treatment of diseases through innovative coating and product integration.

What role do partnerships play in Surmodics' business model?

Partnerships are crucial as they enable Surmodics to integrate diverse technical expertise and resources, facilitating the development of customized solutions for some of the world’s leading medical device and diagnostic companies.

How does Surmodics ensure product quality and innovation?

With a strong focus on research and development, Surmodics continually invests in new technologies and manufacturing processes, ensuring that its products meet high standards of performance and reliability.

In which market segments does Surmodics operate?

Surmodics operates primarily in the medical device, diagnostics, and life sciences segments, offering both advanced coating technologies and integrated product solutions tailored to these markets.

Can you explain the evolution of Surmodics' product offerings?

Initially known for its coating technologies, Surmodics has expanded its portfolio through recent acquisitions to offer whole-product solutions, catering to increasingly complex challenges in disease detection and treatment.
Surmodics Inc

Nasdaq:SRDX

SRDX Rankings

SRDX Stock Data

549.47M
13.74M
3.41%
87.05%
1.9%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
EDEN PRAIRIE